Skip to main content
SpringerLink
Log in

Kallikrein-related peptidase 13: an independent indicator of favorable prognosis for patients with nonsmall cell lung cancer

  • Research Article
  • Published:
Tumor Biology

Abstract

The KLK13 gene is dysregulated in several carcinomas, and its expression levels seem to be associated with disease prognosis. The aim of our study was to investigate the prognostic potential of KLK13 mRNA expression for patients with nonsmall cell lung cancer (NSCLC). Total RNA was isolated from cancerous and normal tissues from a cohort of 128 NSCLC patients. The KLK13 mRNA transcription levels were measured using a sensitive quantitative RT-PCR method. The results were normalized by dividing the KLK13 mRNA values with the geometric mean of mRNA expression from four reference genes: beta-actin, TATA-binding protein, hypoxanthine phosphoribosyltransferase 1, and acidic ribosomal phosphoprotein P0. The malignant tissues from the majority of patients (59.3 %) contained significantly more KLK13 mRNA transcripts than did the paired nonmalignant tissues (median difference 11.1-fold, P = 0.008). KLK13 was expressed at higher levels in females than that in males (P = 0.021). No other statistically significant association with clinicopathological data was observed. Kaplan-Meier survival analyses demonstrated that patients with KLK13-positive tumors survived significantly longer than those with KLK13-negative ones (P = 0.009). KLK13 expression was also shown to be able to stratify high-risk individuals among patients with early disease stages (P = 0.030). Multivariate Cox regression analysis showed that KLK13 expression is a favorable, independent prognostic indicator of overall survival (OS) (P = 0.024). Our results suggest that KLK13 mRNA expression constitutes a novel biomarker for the prediction of overall survival in NSCLC and that its quantitative assessment in tumor tissues can aid in treatment decision making.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Abbreviations

KLK :

Kallikrein-related peptidase

NSCLC :

Nonsmall cell lung cancer

pTNM :

Postsurgical pathologic tumor node metastasis

Cp :

Crossing point

HR :

Hazard ratio

CI :

Confidence interval

ADC :

Adenocarcinoma

SCC :

Squamous cell carcinoma

OSCC :

Oral squamous cell carcinoma

References

  1. Tsuboi M, Ohira T, Saji H, Miyajima K, Kajiwara N, Uchida O, et al. The present status of postoperative adjuvant chemotherapy for completely resected non-small cell lung cancer. Ann Thorac Cardiovasc Surg. 2007;13(2):73–7.

    PubMed  Google Scholar 

  2. Eissa A, Diamandis EP. Human tissue kallikreins as promiscuous modulators of homeostatic skin barrier functions. Biol Chem. 2008;389(6):669–80.

    Article  CAS  PubMed  Google Scholar 

  3. Chao J, Shen B, Gao L, Xia CF, Bledsoe G, Chao L. Tissue kallikrein in cardiovascular, cerebrovascular and renal diseases and skin wound healing. Biol Chem. 2010;391(4):345–55.

    Article  CAS  PubMed  Google Scholar 

  4. Bayani J, Diamandis EP. The physiology and pathobiology of human kallikrein-related peptidase 6 (KLK6). Clin Chem Lab Med. 2011;50(2):211–33.

    PubMed  Google Scholar 

  5. Avgeris M, Mavridis K, Scorilas A. Kallikrein-related peptidases in prostate, breast, and ovarian cancers: from pathobiology to clinical relevance. Biol Chem. 2012;393(5):301–17.

    Article  CAS  PubMed  Google Scholar 

  6. Emami N, Diamandis EP. Utility of kallikrein-related peptidases (KLKs) as cancer biomarkers. Clin Chem. 2008;54(10):1600–7.

    Article  CAS  PubMed  Google Scholar 

  7. Schmitt M, Magdolen V. Using kallikrein-related peptidases (KLK) as novel cancer biomarkers. Thromb Haemost. 2009;101(2):222–4.

    CAS  PubMed  Google Scholar 

  8. Schmitt M, Magdolen V, Yang F, Kiechle M, Bayani J, Yousef GM, et al. Emerging clinical importance of the cancer biomarkers kallikrein-related peptidases (KLK) in female and male reproductive organ malignancies. Radiol Oncol. 2013;47(4):319–29.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Luo LY, Diamandis EP, Look MP, Soosaipillai AP, Foekens JA. Higher expression of human kallikrein 10 in breast cancer tissue predicts tamoxifen resistance. Br J Cancer. 2002;86(11):1790–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Mavridis K, Talieri M, Scorilas A. KLK5 gene expression is severely upregulated in androgen-independent prostate cancer cells after treatment with the chemotherapeutic agents docetaxel and mitoxantrone. Biol Chem. 2010;391(4):467–74.

    Article  CAS  PubMed  Google Scholar 

  11. Florou D, Mavridis K, Scorilas A. The kallikrein-related peptidase 13 (KLK13) gene is substantially up-regulated after exposure of gastric cancer cells to antineoplastic agents. Tumour Biol. 2012;33(6):2069–78.

    Article  CAS  PubMed  Google Scholar 

  12. Shaw JL, Diamandis EP. Distribution of 15 human kallikreins in tissues and biological fluids. Clin Chem. 2007;53(8):1423–32.

    Article  CAS  PubMed  Google Scholar 

  13. Planque C, Blechet C, Ayadi-Kaddour A, Heuze-Vourc'h N, Dumont P, Guyetant S, et al. Quantitative RT-PCR analysis and immunohistochemical localization of the kallikrein-related peptidases 13 and 14 in lung. Biol Chem. 2008;389(6):781–6.

    Article  CAS  PubMed  Google Scholar 

  14. Yousef GM, Chang A, Diamandis EP. Identification and characterization of KLK-L4, a new kallikrein-like gene that appears to be down-regulated in breast cancer tissues. J Biol Chem. 2000;275(16):11891–8.

    Article  CAS  PubMed  Google Scholar 

  15. Petraki CD, Gregorakis AK, Papanastasiou PA, Karavana VN, Luo LY, Diamandis EP. Immunohistochemical localization of human kallikreins 6, 10 and 13 in benign and malignant prostatic tissues. Prostate Cancer Prostatic Dis. 2003;6(3):223–7.

    Article  CAS  PubMed  Google Scholar 

  16. Darling MR, Jackson-Boeters L, Daley TD, Diamandis EP. Human kallikrein 13 expression in salivary gland tumors. Int J Biol Markers. 2006;21(2):106–10.

    Article  CAS  Google Scholar 

  17. Konstantoudakis G, Florou D, Mavridis K, Papadopoulos IN, Scorilas A. Kallikrein-related peptidase 13 (KLK13) gene expressional status contributes significantly in the prognosis of primary gastric carcinomas. Clin Biochem. 2010;43(15):1205–11.

    Article  CAS  PubMed  Google Scholar 

  18. Ishige S, Kasamatsu A, Ogoshi K, Saito Y, Usukura K, Yokoe H, et al. Decreased expression of kallikrein-related peptidase 13: Possible contribution to metastasis of human oral cancer. Mol Carcinog. 2013. doi:10.1002/mc.22007.

    PubMed  Google Scholar 

  19. Chang A, Yousef GM, Scorilas A, Grass L, Sismondi P, Ponzone R, et al. Human kallikrein gene 13 (KLK13) expression by quantitative RT-PCR: an independent indicator of favourable prognosis in breast cancer. Br J Cancer. 2002;86(9):1457–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. White NM, Mathews M, Yousef GM, Prizada A, Popadiuk C, Dore JJ. KLK6 and KLK13 predict tumor recurrence in epithelial ovarian carcinoma. Br J Cancer. 2009;101(7):1107–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002;3(7):RESEARCH0034

  22. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252–9.

    Article  CAS  PubMed  Google Scholar 

  23. Altman DG. Suboptimal analysis using ‘optimal’ cutpoints. Br J Cancer. 1998;78(4):556–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Sher YP, Chou CC, Chou RH, Wu HM, Wayne Chang WS, Chen CH, et al. Human kallikrein 8 protease confers a favorable clinical outcome in non-small cell lung cancer by suppressing tumor cell invasiveness. Cancer Res. 2006;66(24):11763–70.

    Article  CAS  PubMed  Google Scholar 

  25. Magklara A, Scorilas A, Katsaros D, Massobrio M, Yousef GM, Fracchioli S, et al. The human KLK8 (neuropsin/ovasin) gene: identification of two novel splice variants and its prognostic value in ovarian cancer. Clin Cancer Res. 2001;7(4):806–11.

    CAS  PubMed  Google Scholar 

  26. Yousef GM, Kyriakopoulou LG, Scorilas A, Fracchioli S, Ghiringhello B, Zarghooni M, et al. Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: a new independent and favorable prognostic marker. Cancer Res. 2001;61(21):7811–8.

    CAS  PubMed  Google Scholar 

  27. Yousef GM, Scorilas A, Nakamura T, Ellatif MA, Ponzone R, Biglia N, et al. The prognostic value of the human kallikrein gene 9 (KLK9) in breast cancer. Breast Cancer Res Treat. 2003;78(2):149–58.

    Article  CAS  PubMed  Google Scholar 

  28. Sasaki H, Kawano O, Endo K, Suzuki E, Haneda H, Yukiue H, et al. Decreased kallikrein 11 messenger RNA expression in lung cancer. Clin Lung Cancer. 2006;8(1):45–8.

    Article  CAS  PubMed  Google Scholar 

  29. Shigemasa K, Gu L, Tanimoto H, O'Brien TJ, Ohama K. Human kallikrein gene 11 (KLK11) mRNA overexpression is associated with poor prognosis in patients with epithelial ovarian cancer. Clin Cancer Res. 2004;10(8):2766–70.

    Article  CAS  PubMed  Google Scholar 

  30. Patsis C, Yiotakis I, Scorilas A. Diagnostic and prognostic significance of human kallikrein 11 (KLK11) mRNA expression levels in patients with laryngeal cancer. Clin Biochem. 2012;45(9):623–30.

    Article  CAS  PubMed  Google Scholar 

  31. Zhang Y, Song H, Miao Y, Wang R, Chen L. Frequent transcriptional inactivation of Kallikrein 10 gene by CpG island hypermethylation in non-small cell lung cancer. Cancer Sci. 2009;101(4):934–40.

    Article  PubMed  Google Scholar 

  32. Chou RH, Lin SC, Wen HC, Wu CW, Chang WS. Epigenetic activation of human kallikrein 13 enhances malignancy of lung adenocarcinoma by promoting N-cadherin expression and laminin degradation. Biochem Biophys Res Commun. 2011;409:442–7.

    Article  CAS  PubMed  Google Scholar 

  33. Batevik R, Grong K, Segadal L, Stangeland L. The female gender has a positive effect on survival independent of background life expectancy following surgical resection of primary non-small cell lung cancer: a study of absolute and relative survival over 15 years. Lung Cancer. 2005;47(2):173–81.

    Article  PubMed  Google Scholar 

  34. Caldarella A, Crocetti E, Comin CE, Janni A, Pegna AL, Paci E. Gender differences in non-small cell lung cancer: a population-based study. Eur J Surg Oncol. 2007;33(6):763–8.

    Article  CAS  PubMed  Google Scholar 

  35. Pitz MW, Musto G, Navaratnam S. Sex as an independent prognostic factor in a population-based non-small cell lung cancer cohort. Can Respir J. 2013;20(1):30–4.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Wu JY, Wang J, Lai JC, Cheng YW, Yeh KT, Wu TC, et al. Association of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation with p53 mutation occurrence in non-small cell lung cancer with different histology, gender, and smoking status. Ann Surg Oncol. 2008;15(11):3272–7.

    Article  PubMed  Google Scholar 

  37. Lai JC, Wu JY, Cheng YW, Yeh KT, Wu TC, Chen CY, et al. O6-Methylguanine-DNA methyltransferase hypermethylation modulated by 17beta-estradiol in lung cancer cells. Anticancer Res. 2009;29(7):2535–40.

    CAS  PubMed  Google Scholar 

  38. Planque C, Li L, Zheng Y, Soosaipillai A, Reckamp K, Chia D, et al. A multiparametric serum kallikrein panel for diagnosis of non-small cell lung carcinoma. Clin Cancer Res. 2008;14(5):1355–62.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The English text was edited by Dr. Owen Parkes. We thank Prof. Pascal Dumont (Tours Hospital) and Lysiane Brick, Géraldine Meunier, Alexandra Fayault, and Aliette Decock-Giraudaud (CIC INSERM 202) for their help in collecting tissues and clinical data. This work was supported by funds from the Ligue Contre le Cancer (Comités d’Indre et Loire, du Morbihan et de la Sarthe).

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. INSERM, UMR 1100, F-37032, Tours, France

    Fabien Gueugnon, Agnès Petit-Courty, Sylvain Marchand-Adam, Serge Guyetant & Yves Courty

  2. Université François Rabelais, EA 6305, F-37032, Tours, France

    Aurélia Barascu

  3. Centre d’Etude des Pathologies Respiratoires, UMR 1100/EA6305, F-37032, Tours, France

    Fabien Gueugnon, Aurélia Barascu, Agnès Petit-Courty, Sylvain Marchand-Adam, Serge Guyetant & Yves Courty

  4. Department of Biochemistry and Molecular Biology, University of Athens, Panepistimiopolis, Athens, 15701, Greece

    Konstantinos Mavridis & Andreas Scorilas

  5. CIC INSERM 1415, Faculté de Médecine, Tours, France

    Valérie Gissot

Authors
  1. Fabien Gueugnon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aurélia Barascu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Konstantinos Mavridis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Agnès Petit-Courty
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sylvain Marchand-Adam
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Valérie Gissot
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Andreas Scorilas
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Serge Guyetant
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yves Courty
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yves Courty.

Electronic supplementary material

Below is the link to the electronic supplementary material.

ESM 1

(DOCX 14 kb)

ESM 2

(RTF 150 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gueugnon, F., Barascu, A., Mavridis, K. et al. Kallikrein-related peptidase 13: an independent indicator of favorable prognosis for patients with nonsmall cell lung cancer. Tumor Biol. 36, 4979–4986 (2015). https://doi.org/10.1007/s13277-015-3148-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-015-3148-1

Keywords

Search

Navigation